Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens
- 17 September 2014
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 7 (6) , 483-493
Abstract
Synthetic cannabinoid intake is an ongoing health issue worldwide, with new compounds continually emerging, making drug testing complex. Parent synthetic cannabinoids are rarely detected in urine, the most common matrix employed in workplace drug testing. Optimal identification of synthetic cannabinoid markers in authentic urine specimens and correlation of metabolite concentrations and toxicities would improve synthetic cannabinoid result interpretation. We screened 20 017 randomly collected US military urine specimens between July 2011 and June 2012 with a synthetic cannabinoid immunoassay yielding 1432 presumptive positive specimens. We analyzed all presumptive positive and 1069 negative specimens with our qualitative synthetic cannabinoid liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method, which confirmed 290 positive specimens. All 290 positive and 487 randomly selected negative specimens were quantified with the most comprehensive urine quantitative LC‐MS/MS method published to date; 290 specimens confirmed positive for 22 metabolites from 11 parent synthetic cannabinoids. The five most predominant metabolites were JWH‐018 pentanoic acid (93%), JWH‐N‐hydroxypentyl (84%), AM2201 N‐hydroxypentyl (69%), JWH‐073 butanoic acid (69%), and JWH‐122 N‐hydroxypentyl (45%) with 11.1 (0.1‐2,434), 5.1 (0.1‐1,239), 2.0 (0.1‐321), 1.1 (0.1‐48.6), and 1.1 (0.1‐250) µg/L median (range) concentrations, respectively.Alkyl hydroxy and carboxy metabolites provided suitable biomarkers for 11 parent synthetic cannabinoids; although hydroxyindoles were also observed. This is by far the largest data set of synthetic cannabinoid metabolites urine concentrations from randomly collected workplace drug testing specimens rather than acute intoxications or driving under the influence of drugs. These data improve the interpretation of synthetic cannabinoid urine test results and suggest suitable urine markers of synthetic cannabinoid intake. This article is a U.S. Government work and is in the public domain in the USA.Keywords
Funding Information
- U.S. Department of War (Y3-DA-1116-01)
This publication has 49 references indexed in Scilit:
- Impact of Prolonged Cannabinoid Excretion in Chronic Daily Cannabis Smokers' Blood on Per Se Drugged Driving LawsClinical Chemistry, 2013
- Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findingsAddiction, 2012
- Identification of Synthetic Cannabinoids in Herbal Incense Blends in the United StatesJournal of Forensic Sciences, 2012
- LC–MS/MS method for the quantitation of metabolites of eight commonly-used synthetic cannabinoids in human urine – An Australian perspectiveJournal of Chromatography B, 2012
- The detection of the urinary metabolites of 3‐[(adamantan‐1‐yl)carbonyl]‐1‐pentylindole (AB‐001), a novel cannabimimetic, by gas chromatography‐mass spectrometryDrug Testing and Analysis, 2011
- Liquid Chromatography-Tandem Mass Spectrometry Analysis of Urine Specimens for K2 (JWH-018) MetabolitesJournal of Analytical Toxicology, 2011
- Solid-Phase Extraction and Quantitative Measurement of Omega and Omega-1 Metabolites of JWH-018 and JWH-073 in Human UrineAnalytical Chemistry, 2011
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and ActivityPLOS ONE, 2011
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human UrineAnalytical Chemistry, 2011
- Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2010